(NasdaqGM:APPN), Third quarter cloud subscriptions revenue increased 21% year-over-year to $113.6 millionThird quarter total revenue increased 21% year-over-year to $187.0 million MCLEAN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue: Cloud subscriptions revenue was $113.6 […]
(NASDAQ:QURE), LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET.
Taco John's Rolls Out Special Offers to Support Community Food Banks and Honor Veterans this Month GlobeNewswire November 06, 2025 ST. LOUIS PARK, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) — This month, Taco John's(R) is giving fans more reason to feel good about their favorite tacos and burritos by donating to local food banks and
Appian Announces Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 Third quarter cloud subscriptions revenue increased 21% year-over-year to $113.6 millionThird quarter total revenue increased 21% year-over-year to $187.0 million MCLEAN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2025. Third
uniQure to Announce Third Quarter 2025 Financial Results ~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~ GlobeNewswire November 06, 2025 LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical
Mwyngil Therapeutics Inc., a biopharmaceutical company dedicated to developing first-in-class and best-in-class small-molecule therapies targeting cardiovascular, metabolic, and chronic inflammatory and immune diseases, today announced the in-licensing of several lead GPR75 modulator molecules and a proprietary cell-surface discovery platform fromExpert Systems Inc. https://mma.prnewswire.com/media/2815640/Mwyngil_logo_Logo.jpg The collaboration expands Mwyngil's leadership in inflammasome and metabolic pathway modulation and
Algernon Health Announces Private Placement GlobeNewswire November 06, 2025 VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce a non-brokered private placement for gross proceeds of $500,000 (the “Offering”) of units (the “Units”) at
NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or the "Company") (NASDAQ:FTNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ:CYTK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants
NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Baxter International, Inc. ("Baxter" or the "Company") (NYSE:BAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are